

(1)

wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C_1-C_5 alkyl, sugar residue, -OR^1, and –$OCOR^2$;

wherein R^1 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl; and

R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5; and

wherein the disease accompanied by a decrease in bone weight is any of menopausal or post-menopausal diseases.

9. (Amended) The composition according to Claim 1, wherein the compound represented by Formula (1) is substituted at least as follows:



wherein A^3, A^5, and B^4 are the same or different and are independently selected from the group consisting of hydroxyl, sugar residue, and –$OCOR^2$;

wherein R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl.

11. (Amended) A method for preventing or treating diseases accompanied by a decrease in bone weight by taking or administrating an effective amount of at least one member selected from the compound represented by Formula (1) or a multimer thereof:



(1)

wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C_1-C_5 alkyl, sugar residue, -OR^1, and –$OCOR^2$;

wherein R^1 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl; and

R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5.

12. (Amended) A preventative or therapeutic composition for hypertension or a disease resulting from hypertension, the composition containing, as an active component, at least one member selected from the compound represented by Formula (1) or a multimer thereof:



(1)

wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C_1-C_5 alkyl, sugar residue, -OR^1, and –$OCOR^2$;

wherein R^1 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl; and

R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5.

15. (Amended) The composition according to Claim 12, wherein the hypertension and diseases resulting from hypertension is present in menopausal or post-menopausal period.

18. (Amended) The composition according to Claim 12, wherein the compound represented by Formula (1) is substituted at least as follows:



wherein A^3, A^5, and B^4 are the same or different and are independently selected from the group consisting of hydroxyl, sugar residue, and $-OCOR^2$;

wherein R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl.

19. (Amended) A method for preventing or treating hypertension and diseases resulting from hypertension by taking or administrating an effective amount of at least one member selected from the compound represented by Formula (1) or a multimer thereof:



(1)

wherein A and B are the same or different and are independently selected from the group consisting of halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, phosphate, carboxy, hydroxy C_1-C_5 alkyl, sugar residue, $-OR^1$, and $-OCOR^2$;

wherein R^1 is selected from the group consisting of hydrogen, C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl; and

R^2 is selected from the group consisting of C_1-C_5 alkyl, hydroxy C_1-C_5 alkyl, and C_2-C_5 alkenyl;

n is number of substituents A present and is a number from 0 to 5; and

m is number of substituents B present and is a number from 0 to 5.

Please add the following new Claims:

20. (New) The method according to Claim 11, wherein the disease accompanied by a decrease in bone weight is any of menopausal or postmenopausal diseases.

21. (New) The method according to Claim 11, wherein said compound is part of a pharmaceutical formulation.

22. (New) The method according to Claim 11, wherein said compound is part of a food product.

23. (New) The method according to Claim 11, wherein the disease accompanied by a decrease in bone weight is a disease accompanied by resorption of alveolar bone.

24. (New) The method according to Claim 23, wherein said compound is adapted for oral administration performed by a medium selected from the group consisting of dentifrice, liquid dentifrice, mouthwash, mouth spray, oral liniment, swab, and floss.

25. (New) The method according to Claim 11, wherein the compound represented by Formula (1) is obtained from at least one plant selected from the group consisting of plants of

Polygonaceae family, plants of Vitaceae family, white hellebore (Veratrum album), mulberry, and peanut.

26. (New) The method according to Claim 19, wherein said compound is part of a pharmaceutical formulation.

27. (New) The method according to Claim 19, wherein said compound is part of a food product.

28. (New) The method according to Claim 19, wherein hypertension or the disease resulting from hypertension is present in menopausal or post-menopausal period.

29. (New) The method according to Claim 19, wherein the compound represented by Formula (1) is obtained from at least one plant selected from the group consisting of plants of Polygonaceae family, plants of Vitaceae family, white hellebore (Veratrum album), mulberry, and peanut.

REMARKS

Claims 1, 9, 11, 12, 15, 18, and 19 have been amended, Claim 4 have been cancelled without prejudice, and Claims 20-29 have been added. As a result, Claims 1-3 and 5-29 remain pending in the present application. Support for the amendments is found in the existing claims and specification and claims as filed. Accordingly, the amendments do not constitute the addition of new matter. Reconsideration of the application in view of the foregoing amendments and following comments is respectfully requested.

The specific changes to the specification and the amended claims are shown on a separated set of pages attached hereto and entitled VERSION WITH MARKINGS TO SHOW CHANGES MADE, which follows the signature page of this Amendment. On this set of pages, the insertions are underlined while **[the deletions are bolded and bracketed]**.